Showing 3941-3950 of 8217 results for "".
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Atopic Dermatitis Linked to Peripheral Vascular Diseasehttps://practicaldermatology.com/news/atopic-dermatitis-linked-peripheral-vascular-disease/2468444/People with atopic dermatitis (AD) are almost twice as likely to develop peripheral vascular disease (PVD), Yale School of Medicine researchers found in a new study. “Associated between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Pro
- ZORYVE Foam Approved in Canada for Seborrheic Dermatitishttps://practicaldermatology.com/news/zoryve-foam-approved-canada-seborrheic-dermatitis/2468434/Health Canada has approved ZORYVE (roflumilast) foam 0.3% for treating seborrheic dermatitis in individuals aged nine and older, according to a press release from Arcutis. The approval makes ZORYVE the first new topical treatment for the condition approved in Canada in over 20 years. The a
- World Hair Transplant Repair Day Set for November 11https://practicaldermatology.com/news/world-hair-transplant-repair-day-set-november-11/2468428/The International Society of Hair Restoration Surgery (ISHRS) will host its annual “World Hair Transplant Repair Day” on November 11, part of the ISHRS’s Fight the FIGHT (an acronym for Fight the Fraudulent, Illicit, and Global Hair Transplants) global consumer awareness campaign designed to educ
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants